A study led by UNC Lineberger Comprehensive Cancer Center members Hanna Sanoff and Stacie Dusetzina found that the liver cancer drug sorafenib does not deliver on its promise of 11 months of longer life for some advanced liver patients, and can come with serious side effects and significant out-of-pocket costs.
Published in the journal Science, a study by UNC School of Medicine researchers offers a new route to design the 'cellular machines' needed to understand and battle diseases.
The week of May 6-12 is National Nurses Week. At the UNC Lineberger Comprehensive Cancer Center and the N.C. Cancer Hospital, we've got some of the best. Read this Q&A with Ashley Farmer, BSN, RN, OCN, patient services manager in the Adult Oncology Infusion Center at UNC Hospitals.
Targeting melanoma, lymphoma: Study finds investigational compound active against cancer driven by genetic mutation
Norman Sharpless, MD, and colleagues reported in Nature Medicine findings from a preclinical study that demonstrated that a potential new drug effectively targeted a genetic mutation linked to melanoma and the most common form of lymphoma.